Minnesota SF 2645: Resolution calling for an end to the cold genocide and forced organ harvesting from Falun Gong practitioners in China

Bill Text

1.1 A bill for an act​
1.2 relating to health; permitting Formulary Committee members with a potential​
1.3 conflict of interest to participate in committee communications and discussions;​
1.4 requiring the commissioner of human services to develop a public comment process​
1.5 for recommendations to the Formulary Committee; requiring the Formulary​
1.6 Committee to seek expertise from the Minnesota Rare Disease Advisory Council;​
1.7 amending Minnesota Statutes 2024, section 256B.0625, subdivisions 13c, 13f,​
1.8 13g.​
1.9 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:​
1.10 Section 1. Minnesota Statutes 2024, section 256B.0625, subdivision 13c, is amended to​
1.11 read:​
1.12 Subd. 13c.Formulary Committee.(a) The commissioner, after receiving​
1.13 recommendations from professional medical associations and professional pharmacy​
1.14 associations, and consumer groups shall designate a Formulary Committee to carry out​
1.15 duties as described in subdivisions 13 to 13g.​
1.16 (b) The Formulary Committee shall be comprised of at least five licensed physicians​
1.17 actively engaged in the practice of medicine in Minnesota, one of whom is an actively​
1.18 practicing psychiatrist, one of whom specializes in the diagnosis and treatment of rare​
1.19 diseases, one of whom specializes in pediatrics, and one of whom actively treats persons​
1.20 with disabilities; at least three licensed pharmacists actively engaged in the practice of​
1.21 pharmacy in Minnesota, one of whom practices outside the metropolitan counties listed in​
1.22 section 473.121, subdivision 4, one of whom practices in the metropolitan counties listed​
1.23 in section 473.121, subdivision 4, and one of whom is a practicing hospital pharmacist; at​
1.24 least two consumer representatives, all of whom must have a personal or professional​
1.25 connection to medical assistance; and one representative designated by the Minnesota Rare​
1​Section 1.​
25-04329 as introduced​03/10/25 REVISOR AGW/NS​
SENATE​
STATE OF MINNESOTA​
S.F. No. 2645​NINETY-FOURTH SESSION​
(SENATE AUTHORS: BOLDON, Lieske and Kupec)​
OFFICIAL STATUS​D-PG​DATE​
Introduction and first reading​865​03/17/2025​
Referred to Health and Human Services​

2.1 Disease Advisory Council established under section 256.4835; the remainder to be made​
2.2 up of health care professionals who are licensed in their field and have recognized knowledge​
2.3 in the clinically appropriate prescribing, dispensing, and monitoring of covered outpatient​
2.4 drugs.​
2.5 (c) Members of the Formulary Committee shall not be employed by the Department of​
2.6 Human Services or have a personal interest in a pharmaceutical company, pharmacy benefits​
2.7 manager, health plan company, or their affiliate organizations, but the committee shall be​
2.8 staffed by an employee of the department who shall serve as an ex officio, nonvoting member​
2.9 of the committee.​
2.10 (d) For the purposes of this subdivision, "personal interest" means that a person owns​
2.11 at least five percent of the voting interest or equity interest in the entity, the equity interest​
2.12 owned by a person represents at least five percent of that person's net worth, or more than​
2.13 five percent of a person's gross income for the preceding year was derived from the entity.​
2.14 (e) A committee member must notify the committee of any potential conflict of interest​
2.15 and recuse themselves from any communications, discussion, or vote on any matter where​
2.16 a conflict of interest exists. A conflict of interest alone, without a personal interest, does​
2.17 not preclude an applicant from serving as a member of the Formulary Committee. The​
2.18 commissioner must publicly disclose any conflict of interest form submitted by a committee​
2.19 member on the Department of Human Services' website at least 48 hours before any meeting​
2.20 of the Formulary Committee that includes the drug subject to the conflict of interest on the​
2.21 agenda.​
2.22 (f) Members may be removed from the committee for cause after a recommendation for​
2.23 removal by a majority of the committee membership. For the purposes of this subdivision,​
2.24 "cause" does not include offering a differing or dissenting clinical opinion on a drug or drug​
2.25 class.​
2.26 (g) The department's medical director shall also serve as an ex officio, nonvoting member​
2.27 for the committee.​
2.28 (h) Committee members shall serve three-year terms and may be reappointed twice by​
2.29 the commissioner.​
2.30 (i) The committee members shall vote on a chair and vice chair from among their​
2.31 membership. The chair shall preside over all committee meetings, and the vice chair shall​
2.32 preside over the meetings if the chair is not present.​
2​Section 1.​
25-04329 as introduced​03/10/25 REVISOR AGW/NS​

3.1 (j) The Formulary Committee shall meet at least three times per year. The commissioner​
3.2 may require more frequent Formulary Committee meetings as needed.